Dr. David Nathan is the Massachusetts General Hosptial's Diabetes Center Director and he says that when it comes to predicting advances in medicine and medical science "crystal balls are notoriously inaccurate." But he and other medical professionals think their predictions in the field of combating diabetes will prove valid. And a CBS News Jan. 9 report appears to prove him right.
FDA officials have finally approved a Type 2 diabetes pill for use in the fight against this insidious disease which results when someone has a shortage of insulin in their body naturally, or their body cannot use what they do have. And that's where Farxiga (dapagliflozin) is supposed to help.
Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and Farxiga provides an additional treatment option for millions of Americans with Type 2 diabetes," said Curtis Rosebraugh, M.D., M.P.H., and director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research.
Type 2 diabetes sufferers number 24 million in America, including such celebrities as Tom Hanks, Halle Berry and Paula Deen. But that still did not prompt the FDA to rush approval of this new SGLT-2 inhibitor drug. And that's because the potential risks from using this drug are serious, including bladder cancer and heart disease. And that is why the drug oversight agency has ordered that six post-marketing studies be conducted to monitor how this new co-developed diabetes pill by Bristol-Myers Squib Co and Astra Zeneca actually impacts users.
Dr. Nathan of Massachusetts General told Medpage Today that the Type 2 diabetes pill development is but one of the advances he sees for 2014 for those who suffer with blood sugar issues. Individuals who have Type 1 diabetes can also look forward to a future artificial pancreas sometime down the road.
There's a large amount of work going on in developing bionic pancreases, that will, essentially, auto-regulate glucose control,' he said. And he thinks that will be the big news people hear about in 2014.
For now, the Farxiga (dapagliflozin) diabetes pill has been approved for sale on the market with FDA approval, and it promises to block reabsorption of glucose by the kidney, sending more of it out through a person's urine daily.
The FDA warns, however, that this drug should not be used by those who have bladder cancer or kidney disease, and that they cannot rule out the possibility of cancer and heart risk by using the new diabetes pill. But they believed the benefits outweighed the risks, so they allowed its use on the market, since high blood sugar can also increase the risk of heart disease, kidney damage and more.
Your doctor and you will have to determine if the risks are too great for use by you or not. And it might be wise to wait until the six monitoring studies have been completed before you become one of those who start using the new Type 2 diabetes drug Farxiga.
It should also be noted that Bristol-Myers Squib Co and Astra Zenecca are not the only manufacturers for this new diabetes miracle pill, as Johnson and Johnson has Invokana. Additionally, Boehringer Ingelheim, along with other drug manufacturers, are developing their own SGLT-2 inhibitor drug for this medical problem too. And won't it be wonderful if the miracle pill and the bionic pancreas make it possible soon for those with diabetes to live more normal and healthy lives?